Elderly Primary Insomnia Polysomnographic Study (0928-002)(TERMINATED)

Lundbeck logo

Lundbeck

Status and phase

Terminated
Phase 3

Conditions

Primary Insomnia

Treatments

Drug: MK0928, gaboxadol / Duration of Treatment - 6 weeks
Drug: Comparator: placebo / Duration of Treatment - 6 weeks

Study type

Interventional

Funder types

Industry

Identifiers

NCT00094666
MK0928-002
2004_085
0928-002

Details and patient eligibility

About

The purpose of the study is to test the safety and effectiveness of an Investigational Drug on insomnia in the elderly.

Sex

All

Ages

65+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Elderly patients with a diagnosis of primary insomnia and in good physical and mental health

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems